Nrx Pharmaceuticals Stock Performance
| NRXP Stock | USD 2.08 0.01 0.48% |
NRX Pharmaceuticals holds a performance score of 8 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -3.74, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning NRX Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, NRX Pharmaceuticals is expected to outperform it. Use NRX Pharmaceuticals treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to analyze future returns on NRX Pharmaceuticals.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NRX Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady basic indicators, NRX Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.48 | Five Day Return (11.49) | Year To Date Return (30.43) | Ten Year Return (97.83) | All Time Return (97.83) |
Last Split Factor 1:10 | Last Split Date 2024-04-02 |
1 | Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network ... | 01/02/2025 |
2 | NRx Pharmaceuticals, Inc. Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market - Yahoo Finance | 01/13/2025 |
3 | NRx Pharmaceuticals director resigns, new nominee expected | 01/14/2025 |
4 | Acquisition by Fricker William of 99200 shares of NRX Pharmaceuticals at 3.08 subject to Rule 16b-3 | 01/17/2025 |
5 | NRx Pharmaceuticals, Inc. Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement | 01/21/2025 |
6 | NRx Pharmaceuticals, Inc. Advances Relationship with Anson Funds with 8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt | 01/28/2025 |
7 | Acquisition by Flynn Patrick John of 162660 shares of NRX Pharmaceuticals subject to Rule 16b-3 | 01/31/2025 |
8 | HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Engage BTIG as Financial Advisor - Morningstar | 02/03/2025 |
9 | Acquisition by Michael Abrams of 50000 shares of NRX Pharmaceuticals at 2.94 subject to Rule 16b-3 | 02/07/2025 |
10 | NRx Pharmaceuticals GAAP EPS of -2.36 | 03/17/2025 |
11 | Q4 2024 NRX Pharmaceuticals Inc Earnings Call Transcript | 03/18/2025 |
12 | NRx Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript | 03/21/2025 |
| Begin Period Cash Flow | 4.6 M |
NRX |
NRX Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 142.00 in NRX Pharmaceuticals on December 22, 2024 and sell it today you would earn a total of 66.00 from holding NRX Pharmaceuticals or generate 46.48% return on investment over 90 days. NRX Pharmaceuticals is currently generating 1.3048% in daily expected returns and assumes 12.4291% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than NRX, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NRX Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NRX Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NRX Pharmaceuticals, and traders can use it to determine the average amount a NRX Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.105
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NRXP | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.43 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.3 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average NRX Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NRX Pharmaceuticals by adding it to a well-diversified portfolio.
NRX Pharmaceuticals Fundamentals Growth
NRX Stock prices reflect investors' perceptions of the future prospects and financial health of NRX Pharmaceuticals, and NRX Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NRX Stock performance.
| Return On Equity | -6.83 | ||||
| Return On Asset | -2.25 | ||||
| Current Valuation | 40.32 M | ||||
| Shares Outstanding | 16.92 M | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (18.5 M) | ||||
| Net Income | (25.13 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 6.58 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.59) X | ||||
| Cash Flow From Operations | (10.64 M) | ||||
| Earnings Per Share | (2.37) X | ||||
| Market Capitalization | 35.18 M | ||||
| Total Asset | 3.65 M | ||||
| Retained Earnings | (278.27 M) | ||||
| Working Capital | (18.56 M) | ||||
About NRX Pharmaceuticals Performance
Assessing NRX Pharmaceuticals' fundamental ratios provides investors with valuable insights into NRX Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NRX Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (734.56) | (697.83) | |
| Return On Tangible Assets | (6.88) | (6.54) | |
| Return On Capital Employed | 1.02 | 1.07 | |
| Return On Assets | (6.88) | (6.54) | |
| Return On Equity | 1.08 | 1.14 |
Things to note about NRX Pharmaceuticals performance evaluation
Checking the ongoing alerts about NRX Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NRX Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NRX Pharmaceuticals is way too risky over 90 days horizon | |
| NRX Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (25.13 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NRX Pharmaceuticals currently holds about 24.55 M in cash with (10.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from insidermonkey.com: NRx Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript |
- Analyzing NRX Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NRX Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining NRX Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NRX Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NRX Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NRX Pharmaceuticals' stock. These opinions can provide insight into NRX Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.